Enveric Biosciences (ENVB) EPS (Basic) Growth (5y) (2015 - 2026)
Enveric Biosciences (ENVB) EPS (Basic) Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - |
| 10 | Enveric Biosciences | 5.50 Mn | -2.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.76% |
| Dec 31, 2025 | 68.67% |
| Sep 30, 2025 | 72.82% |
| Jun 30, 2025 | 76.75% |
| Mar 31, 2025 | 76.76% |
| Dec 31, 2024 | 72.13% |
| Sep 30, 2024 | 47.60% |
| Jun 30, 2024 | 71.65% |
| Mar 31, 2024 | 69.11% |
| Dec 31, 2023 | 79.36% |
| Sep 30, 2023 | -14.89% |
| Jun 30, 2023 | 61.54% |
| Mar 31, 2023 | 66.69% |
| Dec 31, 2022 | 58.69% |
| Sep 30, 2022 | 75.35% |
| Jun 30, 2022 | 70.93% |
| Mar 31, 2022 | 58.31% |
| Dec 31, 2021 | -16.92% |
| Sep 30, 2021 | 61.10% |
| Jun 30, 2021 | 66.16% |